Olprinone: A phosphodiesterase III inhibitor with positive inotropic and vasodilator effects

Cardiovascular Drug Reviews

Volumn 20, Issue 3, 2002, Pages 163-174

  Mizushige, Katsufumi ^a   Ueda, Takashi ^a   Yukiiri, Kazushi ^a   Suzuki, Hitoshi ^b  

^a KAGAWA UNIVERSITY   (Japan)

^b EISAI CO LTD   (Japan)

Author keywords

Cerebral blood flow; Heart failure; Olprinone; Phosphodiesterase III inhibitor; Positive inotropism; Vasodilatation

Indexed keywords

6 (3 DIMETHYLAMINOPROPIONYL)FORSKOLIN; ACETAZOLAMIDE; ADENYLATE CYCLASE ACTIVATOR; AMRINONE; CARBON DIOXIDE; DOBUTAMINE; INOTROPIC AGENT; LOPRINONE; MILRINONE; PHOSPHODIESTERASE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE INHIBITOR; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ARTERY COMPLIANCE; BRAIN ARTERY; BRAIN BLOOD FLOW; BRAIN METABOLISM; BRAIN PERFUSION; CAROTID ARTERY; CLINICAL TRIAL; DRUG MECHANISM; DRUG STRUCTURE; HEART FAILURE; HEART MUSCLE; HEART RATE; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; INOTROPISM; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SMOOTH MUSCLE FIBER; TACHYCARDIA; THROMBOCYTOPENIA; VASODILATATION;

EID: 0036398694     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2002.tb00085.x     Document Type: Review

References (52)

1. Ahlgren ÅR, Hansen F, Sonesson B, Lanne T. Stiffness and diameter or the common carotid artery and abdominal aorta in women. Ultrasound Med Biol 1997;23:983-988.
2. Asenbaum S, Brucke T, Pirker W, Pietrzyk U, Podreka I. Imaging of cerebral blood flow with technetium-99m-HMPAO and technetium-99m-ECD: A comparison. J Nucl Med 1998;39:613-618.
3. Barenbrock M, Spieker C, Witta J, et al. Reduced distensibility of the common carotid artery in patients treated with ergotamine. Hypertension 1996;28:115-119.
4. Barenbrock M, Spieker C, Hoeks APG, Zidek W, Rahn KH. Effect of lisinopril and metoprolol on arterial distensibility. Hypertension 1994;23(Suppl I):1161-1163.
5. Bornstein RA, Starling RC, Myerowits PD, Haas GJ. Neuropsychological function in patients with end-stage heart failure before and after cardiac transplantation. Acta Neurol Scand 1995;91:260-265.
6. Bouma GJ, Muizelaar P. Relationship between cardiac output and cerebral blood flow in patients with intact and with impaired autoregulation. J Neurosurg 1990;73:368-374.
7. Challiss RAJ, Nicholson CD. Effects of selective phosphodiesterase inhibition on cyclic AMP hydrolysis in rat cerebral cortical slices. Br J Pharmacol 1990;99:47-52.
8. Chamorro A, Saiz A, Vila N, et al. Contribution of arterial blood pressure to the clinical expression of lacunar infarction. Stroke 1996;27:388-392.
9. Colucci WS, Denniss AR, Leatherman GF, et al. Intracoronary infusion of dobutamine to patients with and without severe congestive heart failure. Dose-response relationships, correlation with circulating catecholamine, and effect of phosphodiesterase inhibition. J Clin Invest 1998;81:1103-1110.
10. Dèmolis P, Carville C, Giudicelli JF. Effects of an angiotensin-converting enzyme inhibitor, lisinopril, on cerebral blood flow autoregulation in healthy volunteers. J Cardiovasc Pharmacol 1993;22:373-380.
11. Dèmolis P, Florence G, Thomas L, Dinh YRT, Giudicelli JF, Seylaz J. Is the acetazolamide test valid for quantitative assessment of maximal cerebral autoregulatory vasodilation? An experimental study. Stroke 2000;31:508-515.
12. Dobrin PB, Rovick AA. Influence of vascular smooth muscle on contractile mechanics and elasticity of arteries. Am J Physiol 1969;217:1644-1651.
13. Fischer GM, Llaurado JG. Collagen and elastin content in canine arteries selected from functionally different vascular beds. Circ Res 1966;19:394-399.
14. Fujimoto S, Ohashi M, Hiramoto A, et al. Vasorelaxant effect of olprinone, an inhibitor of phosphodiesterase 3, on mesenteric small artery and vein of rabbits. Eur J Pharmacol 1998;353:239-246.
15. Georgiadis SD, Cencetti S, Uhlmann F, Krivokuca M, Zierz S, Werdan K. Cerebrovascular reactivity is impaired in patients with cardiac failure. Eur Heart J 2000;21:407-413.
16. Gruhn N, Larsen F, Boesgaard S, et al. Cerebral blood flow in patients with chronic heart failure before and after heart transplantation. Stroke 2001;32:2530-2533.
17. Harris AL, Grant AM, Silver PJ, Evans DB, Alousi AA. Differential vasorelaxant effects of milrinone and amrinone on contractile responses of canine coronary, cerebral, and renal arteries. J Cardiovasc Pharmacol 1989;13:238-244.
18. Harris AL, Wassey ML, Grant AM, Alousi AA. Direct vasodilatory action of milrinone and sodium nitrite in canine coronary artery. Fed Proc 1984;43:938.
19. Harvey BH, Carstens ME, Taljaard JJF. Central effects of the preservative, methylparaben. In vivo activation of cAMP-specific phosphodiesterase and reduction of cortical cAMP. Biochem Phamacol 1992;44: 1053-1057.
20. Hayashi K, Handa H, Nagasawa S, Okumura A, Moritake K. Stiffness and elastic behavior of human intracranial and extracranial arteries. J Biochem 1980;13:175-184.
21. Heistad DD, Marcus ML, Piegors DJ, Armstrong ML. Regulation of cerebral blood flow in atherosclerotic monkeys. Am J Physiol 1980;239:539-544.
22. 2+-independent vasorelaxation induced by cardiotonic phosphodiesterase inhibitors. Eur J Pharmacol 1993;240:57-66.
23. 2 reactivity during hypocapnia in normal subjects. Stroke 1996;27:1328-1332.
24. Kawasaki T, Sasayama S, Yagi S, Asakawa T, Hirai T. Noninvasive assessment of the age related changes in stiffness of major branches of the human arteries. Cardiovasc Res 1987;21:678-687.
25. Kazumata K, Tanaka N, Ishikawa T, Kuroda S, Houkin K, Mitsumori K. Dissociation of vasoreactivity to acetazolamide and hypercapnia. Comparative study in patients with chronic occlusive major cerebral artery disease. Stroke 1996;27:2052-2058.
26. Khajavi K, Ayzman I, Shearer D, et al. Prevention of chronic cerebral vasospasm in dogs with milrinone. Neurosurgery 1997;40:354-363.
27. Kobayashi S, Okada K, Yamashita K. Incidence of silent lacunar lesion in normal adults and its relation to cerebral blood flow and risk factors. Stroke 1991;22:1397-1387.
28. Länne T, Hansen F, Mangell P, Sonesson B. Differences in mechanical properties of the common carotid artery and abdominal aorta in healthy males. J Vasc Surg 1994;20:219-225.
29. Lewis JF, Kuo LC, Nelson JG, Limacher MC, Quinones MA. Pulsed Doppler echocardiographic determination of stroke volume and cardiac output: Clinical validation of two new methods using the apical window. Circulation 1984;70:425-431.
30. Ludmer PL, Wright RF, Arnold MO, Ganz P, Braunwald E, Colucci WS. Separation of the direct myocardial and vasodilator actions of milrinone administered by an intracoronary infusion technique. Circulation 1986; 73:130-137.
31. Miyahara M, Itoh M, Itoh H, et al. Isoenzymes of cyclic nucleotide phosphodiesterase in the human aorta: Characterization and the effects of E4021. Eur J Pharmacol 1995;284:25-33.
32. Murakami R, Sano K, Murakami Y, Shimada T, Morioka S. Effects of intracoronary infusion of an inotropic agent, E-1020 (loprinone hydrochloride), on cardiac function: Evaluation of left ventricular contractile performance using the end-systolic pressure-volume relationship. Int J Cardiol 1995;51:57-63.
33. Ohhara H, Sawada K, Ogawa T, et al. Effects of the new agent loprinone hydrochloride (E-1020) on left ventricular diameter in normal and experimental heart failure dogs and its action potential characteristics in isolated guinea pig cardiac muscle and sinus nodes. Folia Pharmacol Jpn 1992;99:421-433.
34. Ohoka M, Honda M, Morioka S, et al. Effects of E-1020, a new cyclic AMP-specific phosphodiesterase inhibitor, on cyclic AMP and cytosolic free calcium of cultured vascular smooth muscle cells. Jpn Circ J 1990;54:679-687.
35. Onoue H, Katusic ZS. The effect of subarachoid hemorrhage on mechanisms of vasodilation mediated by cyclic adenosine monophosphate. J Neurosurg 1998;89:111-117.
36. Roman DD, Kubo SH, Ormaza S, Francis GS, Bank AJ, Shumway SJ. Memory improvement following cardiac transplantation. J Clin Exp Neuropsychol 1997;19:692-697.
37. Safar ME, Simon AC, Levenson JA, Cazor JL. Hemodynamic effects of diltiazem in hypertension. Circ Res 1983;52(Suppl I):1169-1173.
38. Seki M, Mizushige K, Ueda T, Kitadai M, Matsuo H. Effect of olprinone, phosphodiesterase III inhibitor, on arterial wall distensibility: Differentiation between aorta and common carotid artery. Heart Vessels 1999;14: 224-231.
39. i and force in middle cerebral artery of the rabbit. Br J Pharmacol 1998;123: 869-878.
40. Shuaib A, Lee D, Pelz D, Fox A, Hachinski VC. The impact of magnetic resonance imaging on the management of acute ischemic stroke. Neurology 1992;42:816-818.
41. Sugioka M, Itoh M, Masuoka H, et al. Identification and characterization of isoenzymes of cyclic nucleotide phosphodiesterase in human kidney and heart, and the effects of new cardiotonic agents on these isoenzymes. Naunyn-Schmiedeberg's Arch Pharmacol 1994;350:284-293.
42. Takaoka K, Takeuchi M, Okada M, et al. Comparison of the effects on atrial-ventricular coupling between phosphodiesterase inhibitor and dobutamine in the decreased human heart. J Am Coll Cardiol 1993;22: 598-606.
43. 99mTc-ECD consecutive SPECT method. J Cereb Blood Flow Metab 1997;17:1020-1032.
44. Tanio H, Kumada T, Hayashi M, Nakamura Y, Kawai C. Hemodynamic efficacy of E-1020 in comparison with dopamine on acute mitral regurgitation in anesthetized dogs. Jpn Circ J 1991;55:1068-1076.
45. Tsuchida T, Nishizawa S, Yonekura Y, et al. SPECT images of technetium-99m-ethyl cysteinate dimer in cerebrovascular diseases: Comparison with other cerebral perfusion tracers and PET. J Nucl Med 1994;35: 27-31.
46. Umekawa H, Tanaka H, Kimura Y. Hidaka H. Purification of cyclic adenosine monophosphate phosphodiesterase from human platelets using new-inhibitor sepharose chromatograpghy. Biochem Pharmacol 1984;33: 3339-3344.
47. Wada T, Fujishiro K, Fukumoto T, Yamazaki S. Relationship between ultrasound assessment of arterial wall properties and blood pressure. Angiology 1997;48:893-900.
48. Wanless RB, Anand IS, Gurden J, Harris P, Poole-Wilson PA. Regional blood flow and hemodynamics in the rabbit with adriamycin cardiomyopathy: Effects of isosorbide dinitrate, dobutamine and captopril. J Pharmacol Exp Ther 1987;243:1101-1106.
49. Wroblewski H, Kastrup J, Mortensen SA, Hauns S. Abnormal baroreceptor-mediated vasodilation of the peripheral circulation in congestive heart failure secondary to idiopathic dilated cardiomyopathy. Circulation 1993;87:749-756.
50. Yu Y, Mizushige K, Ueda T, et al. Effect of olprinone, phosphodiesterase III inhibitor, on cerebral blood flow assessed with technetium-99m-ECD SPECT. J Cardiovasc Pharmacol 2000;35:422-426.
51. Yukiiri K, Mizushige K, Ueda T, Nishiyama Y, Aoyama T, Kohno M. Effects of olprinone, a phosphodiesterase 3 inhibitor, on regional cerebral blood flow of cerebral cortex in stroke patients. J Cardiovasc Pharmacol 2001;37:375-380.
52. Zuccala G, Cattel C, Manes-Gravina E, Di Niro MG, Cocchi A, Bervabei R. Left ventricular dysfunction: A clue to cognitive impairment in older patients with heart failure. J Neurol Neurosurg Psychiatry 1997;63: 509-512.